EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Systemic Everolimus Does Not Block the Incubation of Methamphetamine‐Craving: A Dose–Response Study

Fernando J Cano, Kierra E Smith iD, Katherine Stuemke, Asha Jotwani iD, Erin Lassers, Holly M Nelson, Sonya D Adler, Laura L Huerta Sanchez iD, Christopher J E Denning, Samantha M Davantes iD, Citlali A Ibarra, Tod E Kippin iD und 1 weitere

Addiction Biology · 2026

DOI: 10.1111/adb.70189 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Addiction Biology, 2026. Verfasst von Fernando J Cano und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychological and Brain Sciences, University of California Santa Barbara, Santa Barbara, California, USA. Hauptthemen laut MEDLINE: Methamphetamine, Craving, Everolimus, Central Nervous System Stimulants. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDA NIH HHS, National Science Foundation, NINDS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In rodent models, incubated craving for drugs and natural reinforcers is characterized by a time‐dependent increase in cue‐elicited operant responding, which posits that common biochemical mechanisms gate incubated craving across different types of reinforcers. Recently, our laboratory identified heightened mTOR activity in the prelimbic (PL) and infralimbic (IL) subregions of the medial prefrontal cortex (mPFC) as being associated with incubated craving for cocaine and sucrose, respectively. Importantly, Everolimus, an FDA‐approved mTOR inhibitor, blocked the expression of incubated craving for both reinforcers. Hence, our current study investigated whether mTOR signalling also underpins cue‐induced methamphetamine (METH)‐seeking by evaluating the “therapeutic potential” of Everolimus to block incubated METH‐craving. Male and female rats were trained under extended‐access procedures (6‐h/day × 10 days) to self‐administer intravenous METH (0.1 mg/kg/0.1 mL infusion), paired with the presentation of a 20‐s light + tone compound stimulus and then were subjected to a withdrawal period of 1 or 30 days (WD1 or WD30). Rats tested on WD30 were gavage‐infused with either vehicle (VEH; 1% DMSO in water; vol: 1 mL/kg) or Everolimus (1 or 10 mg/kg), whereas WD1 rats were infused with VEH to index baseline craving. Thirty minutes later, rats underwent a 2‐h test to measure cue‐elicited responding. Akt/mTOR activity in the PL and IL was examined via immunoblotting procedures. Male and female rats exhibited comparable METH intake and craving, with no effect of estrous cycle observed for either measure in females. Unlike previous findings for incubated cocaine‐ and sucrose‐craving, Everolimus did not reduce incubated METH‐craving. Further, incubated METH‐craving was not associated with changes in Akt/mTOR activation within mPFC subregions nor did Everolimus lower mTOR pathway activation below baseline levels in either METH‐experienced or –naive rats. Together, these findings demonstrate that elevated mTOR signalling within mPFC is not involved in incubated METH‐craving, highlighting the potential need for drug‐specific targeted treatments for curbing incubated craving in protracted withdrawal.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MethamphetamineCravingEverolimusCentral Nervous System StimulantsDrug-Seeking BehaviorMTOR InhibitorsSirolimusAmphetamine-Related DisordersAnimalsFemaleMaleRatsTOR Serine-Threonine KinasesDose-Response Relationship, DrugSelf AdministrationPrefrontal CortexCuesRats, Sprague-DawleySignal Transduction

Substanzen

MethamphetamineEverolimusTOR Serine-Threonine KinasesCentral Nervous System StimulantsMTOR InhibitorsSirolimusmTOR protein, rat

Autor:innen und Institutionen

  • Department of Psychological and Brain Sciences, University of California Santa Barbara, Santa Barbara, California, USA.

ORCID-Profile: Kierra E Smith, Asha Jotwani, Laura L Huerta Sanchez, Samantha M Davantes, Tod E Kippin, Karen K Szumlinski

Förderung

  • NIDA NIH HHS
  • National Science Foundation
  • NINDS NIH HHS
  • Bill and Melinda Gates Foundation
  • National Institute on Drug Abuse
  • National Institute of Neurological Disorders and Stroke

Zitieren

APA

Cano, F. J., Smith, K. E., Stuemke, K., Jotwani, A., Lassers, E., Nelson, H. M., Adler, S. D., Huerta Sanchez, L. L., Denning, C. J. E., Davantes, S. M., Ibarra, C. A., Kippin, T. E., & Szumlinski, K. K. (2026). Systemic Everolimus Does Not Block the Incubation of Methamphetamine‐Craving: A Dose–Response Study. Addiction Biology. https://doi.org/10.1111/adb.70189

Vancouver

Cano FJ, Smith KE, Stuemke K, Jotwani A, Lassers E, Nelson HM, et al. Systemic Everolimus Does Not Block the Incubation of Methamphetamine‐Craving: A Dose–Response Study. Addiction Biology. 2026. doi:10.1111/adb.70189

BibTeX
@article{Cano2026,
  author = {Cano, Fernando J and Smith, Kierra E and Stuemke, Katherine and Jotwani, Asha and Lassers, Erin and Nelson, Holly M and Adler, Sonya D and Huerta Sanchez, Laura L and Denning, Christopher J E and Davantes, Samantha M and Ibarra, Citlali A and Kippin, Tod E and Szumlinski, Karen K},
  title = {Systemic Everolimus Does Not Block the Incubation of Methamphetamine‐Craving: A Dose–Response Study},
  journal = {Addiction Biology},
  year = {2026},
  doi = {10.1111/adb.70189}
}
Kostenlos starten →